Yes. As of September 2026, Illumina, Inc. (ILMN) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 5.16% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.68% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 5.16% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.68% / 33% · Receivables / Mkt Cap (36m) 2.03% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 5.16% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.68% / 33.33% · Receivables / Mkt Cap (24m) 2.03% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 29.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 19.8% / 33.33% · Receivables / Avg Assets (4Q) 11.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 27.5% / 33.33% · (Cash+ST Inv) / Total Assets 19.6% / 33.33% · (Cash+Recv) / Total Assets 30.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Illumina, Inc. (ILMN) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Illumina, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Illumina, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 27, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Illumina, Inc. (NASDAQ: ILMN) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $29.9B. The Maz Rating grades it against the other companies in its sector.
Illumina, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $198.00, Illumina, Inc. trades at 35.1x trailing earnings, 6.9x sales and 9.9x book value, with an EV/EBITDA of 23.3. Over the last twelve months it generated about $4.3B of revenue and $852M of net income. It runs a gross margin of 68.3%, an operating margin of 22.4% and a net margin of 19.7%. It shows return on equity of 31.5%, return on invested capital of 15.0% and a free cash flow yield of 3.4%. On the balance sheet: a debt-to-equity ratio of 0.74 and a current ratio of 2.63. Over the past 52 weeks the share price ranged from $112.65 to $309.35, with a beta of 1.45.
Illumina, Inc. does not currently pay a dividend.
50 Wall Street analyst ratings cover the stock: 1 Strong Buy, 26 Buy, 17 Hold and 6 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.